Navigation Links
New HPV Vaccine Promising in Mice
Date:4/15/2008

It might cover all types of HPV and be given as a nasal spray, researchers say

TUESDAY, April 15 (HealthDay News) -- Researchers say they've created a synthetic vaccine that can be delivered as a nasal spray for human papillomavirus -- the source of the most common sexually transmitted disease in the United States and a cause of cervical cancer.

The experimental vaccine, tested so far just with mice, also offers protection against different strains of HPV, the researchers said.

The existing vaccine for HPV, called Gardasil, protects against four strains of the virus that are responsible for about 70 percent of all cervical cancers. The Gardasil vaccine requires three injections for full protection.

"We have been trying to produce a single vaccine that would be able to protect patients against all cancer causing HPV types," said Richard B.S. Roden, lead researcher for the new study and an associate professor of pathology, gynecology and obstetrics, and oncology at Johns Hopkins University.

"What we have done is to try to develop a completely synthetic vaccine that would induce antibodies that would neutralize and protect against a whole range of these cancer-causing strains," he added.

The advantages of the synthetic vaccine are that it can be synthesized as if it were a drug, Roden said, adding that "it can be made chemically in the lab rather than having to use biological systems."

A synthetic vaccine also should be cheaper, Roden added. Using this approach, the vaccine could also be given nasally, he said.

"This may be another way to reduce the cost of vaccination, because you don't have to use needles," he said.

The findings are published in the April 15-18 issue of the Proceedings of the National Academy of Sciences.

In their experiments, Roden and his colleagues used a protein from one of the strains of HPV -- HPV16 -- to create a man-made vaccine in the laboratory. When the vaccine was given to mice either by injection or nasal spray, it protected not only against HPV16, but also against another strain of the virus -- HPV45.

Roden said the mice used in this experiments had special immune system T helper cells for the vaccine to attach itself. Whether human T helper cells would work in all groups of people isn't known, he said. "Right now, that's an area we are looking at," he said.

HPV is responsible for genital warts and about 99.7 percent of all cervical cancers worldwide.

Debbie Saslow, director of breast and gynecologic cancer at the American Cancer Society, said that if this vaccine could be developed, it would represent an important advance in getting more people vaccinated against HPV, especially in developing countries.

"While we have wonderful opportunities with the current vaccine, there are limitations," she said.

One limitation is the cost of the Gardasil vaccine, an estimated $300 to $500, Saslow added. "That's a limitation in this country, but particularly in the developing world where there is so much cervical cancer," she said.

The Gardasil vaccine also requires three shots, which is difficult in developing countries and among adolescents, Saslow said.

"Needle-less vaccination is the way to go for a lot of reasons," she said. "The current shots are extremely painful, and that's going to be a deterrent for teenage populations, as is going back and getting the three doses."

More information

To learn more about HPV, visit the U.S. Centers for Disease Control and Prevention.



SOURCES: Richard B.S. Roden, Ph.D., associate professor of pathology, gynecology and obstetrics, and oncology, Johns Hopkins University, Baltimore; Debbie Saslow, Ph.D., director, breast and gynecologic cancer, American Cancer Society, Atlanta; April 15-18, 2008, Proceedings of the National Academy of Sciences


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Breast Cancer Vaccine Works Against Deadlier Form of Disease
2. Boston Trial to Test New HIV/AIDS Vaccine
3. Researchers Pursuing Nasal Anthrax Vaccine
4. Adults Need Protection Against Vaccine-Preventable Diseases, Too
5. Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine
6. Actress/Producer Salma Hayek Launches The Pampers(R) One Pack = One Vaccine Program to Benefit UNICEF
7. Gardasil, Other New Products Spur Strong Vaccine Sales in 2007
8. Alzheimers vaccine clears plaque but has little effect on learning and memory impairment
9. FDA OKs New Rotavirus Vaccine
10. Vaccine Induced Inflammation Linked to Epidemic of Type 2 Diabetes and Metabolic Syndrome
11. FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Horizon Blue ... affirmed the company’s credit rating of “A” and its outlook as “stable.” At the ... capital reserves, which have fallen in recent years, dip below “capital adequacy” thresholds required ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces ... an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start ... 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and maintenance ...
(Date:4/28/2017)... ... ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical organization ... Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord blood ... , “Women’s Hospital at Renaissance has been a collection partner for the TCBB ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Bill Howe ... industry in the coastal communities. After Tina Howe joined the team, the Bill Howe ... employees, honest services at affordable rates, and giving back to the San Diego community ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... work assisting the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that ... a leading ERP expert that specializes in long-term care, Brooke Grove now has ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
Breaking Medicine Technology: